These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27461225)

  • 1. The role of PAQR3 gene promoter hypermethylation in breast cancer and prognosis.
    Chen J; Wang F; Xu J; He Z; Lu Y; Wang Z
    Oncol Rep; 2016 Sep; 36(3):1612-8. PubMed ID: 27461225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant promoter methylation of the PAQR3 gene is associated with prostate cancer.
    Lounglaithong K; Bychkov A; Sampatanukul P
    Pathol Res Pract; 2018 Jan; 214(1):126-129. PubMed ID: 29122400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAQR3 expression is downregulated in human breast cancers and correlated with HER2 expression.
    Li Z; Ling ZQ; Guo W; Lu XX; Pan Y; Wang Z; Chen Y
    Oncotarget; 2015 May; 6(14):12357-68. PubMed ID: 25900239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-15b facilitates breast cancer progression via repressing tumor suppressor PAQR3.
    Qi LQ; Sun B; Yang BB; Lu S
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):740-748. PubMed ID: 32016977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAQR3 overexpression suppresses the aggressive phenotype of esophageal squamous cell carcinoma cells via inhibition of ERK signaling.
    Bai G; Chu J; Eli M; Bao Y; Wen H
    Biomed Pharmacother; 2017 Oct; 94():813-819. PubMed ID: 28802234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer.
    Han LL; Hou L; Zhou MJ; Ma ZL; Lin DL; Wu L; Ge YL
    J Biomed Sci; 2013 Jul; 20(1):52. PubMed ID: 23899187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells.
    Rawat A; Gopisetty G; Thangarajan R
    Cell Oncol (Dordr); 2014 Dec; 37(6):409-19. PubMed ID: 25338303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.
    Fujikane T; Nishikawa N; Toyota M; Suzuki H; Nojima M; Maruyama R; Ashida M; Ohe-Toyota M; Kai M; Nishidate T; Sasaki Y; Ohmura T; Hirata K; Tokino T
    Breast Cancer Res Treat; 2010 Aug; 122(3):699-710. PubMed ID: 19859801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TES was epigenetically silenced and suppressed the epithelial-mesenchymal transition in breast cancer.
    Yongbin Y; Jinghua L; Zhanxue Z; Aimin Z; Youchao J; Yanhong S; Manjing J
    Tumour Biol; 2014 Nov; 35(11):11381-9. PubMed ID: 25119600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Demethylation of estrogen receptor gene and its re-expression in estrogen receptor-negative breast].
    Wang R; Li LW; Wang RL; Fan QX; Zhao PR; Wang LX; Lu SH
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):894-7. PubMed ID: 17533738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma.
    Wu HG; Zhang WJ; Ding Q; Peng G; Zou ZW; Liu T; Cao RB; Fei SJ; Li PC; Yang KY; Hu JL; Dai XF; Wu G; Li PD
    Oncol Rep; 2014 Dec; 32(6):2687-95. PubMed ID: 25310770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer.
    Kikuchi M; Katoh H; Waraya M; Tanaka Y; Ishii S; Tanaka T; Nishizawa N; Yokoi K; Minatani N; Ema A; Kosaka Y; Tanino H; Yamashita K; Watanabe M
    Cancer Lett; 2017 Jan; 384():70-78. PubMed ID: 27756570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant GRK6 promoter methylation is associated with poor prognosis in hypopharyngeal squamous cell carcinoma.
    Qiu X; Chen J; Zhang Z; You Y; Wang Z
    Oncol Rep; 2016 Feb; 35(2):1027-33. PubMed ID: 26718636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
    Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer.
    Liu H; Yan Z; Yin Q; Cao K; Wei Y; Rodriguez-Canales J; Ma D; Wu Y
    J Histochem Cytochem; 2018 Oct; 66(10):709-721. PubMed ID: 30133331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer.
    Kang S; Kim B; Park SB; Jeong G; Kang HS; Liu R; Kim SJ
    Int J Oncol; 2013 Nov; 43(5):1659-65. PubMed ID: 24026393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
    Wahabi K; Perwez A; Kamarudheen S; Bhat ZI; Mehta A; Rizvi MMA
    BMC Cancer; 2019 Aug; 19(1):820. PubMed ID: 31429726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.